Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study.

Christ, Sebastian M; Alongi, Filippo; Ricardi, Umberto; Scorsetti, Marta; Livi, Lorenzo; Balermpas, Panagiotis; Lievens, Yolande; Braam, Pètra; Alicja Jereczek-Fossa, Barbara; Stellamans, Karin; Ratosa, Ivica; Widder, Joachim; Peulen, Heike; Dirix, Piet; Bral, Samuel; Ramella, Sara; Hemmatazad, Hossein; Khanfir, Kaouthar; Geets, Xavier; Jeene, Paul; ... (2024). Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 195(110235), p. 110235. Elsevier Scientific Publ. Ireland 10.1016/j.radonc.2024.110235

Text 1-s2.0-S0167814024001579-main.pdf - Accepted Version Restricted to registered users only until 18 March 2025. Available under License Publisher holds Copyright. Download (953kB)

BACKGROUND AND INTRODUCTION

Optimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation.

MATERIALS AND METHODS

Analysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using α/β of 10 Gy for all primaries, and cancer-specific α/β of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2.5 Gy for breast cancer (BC), or 1.5 Gy for prostate cancer (PC).

RESULTS

Of the interim analysis population of 1,099 patients, 999 (99.5 %) fulfilled inclusion criteria and received metastasis-directed SBRT for NSCLC (n = 195; 19.5 %), BC (n = 163; 16.3 %), CRC (n = 184; 18.4 %), or PC (n = 457; 47.5 %). Two thirds of patients were treated for single metastasis. Median number of fractions was 5 (IQR, 3-5) and median dose per fraction was 9.7 (IQR, 7.7-12.4) Gy. The most frequently treated sites were non-vertebral bone (22.8 %), lung (21.0 %), and distant lymph node metastases (19.0 %). On multivariate analysis, the dose varied significantly for primary cancer type (BC: 237.3 Gy BED, PC 300.6 Gy BED, and CRC 84.3 Gy BED), and metastatic sites, with higher doses for lung and liver lesions.

CONCLUSION

This real-world analysis suggests that SBRT doses are adjusted to the primary cancers and oligometastasis location. Future analysis will address safety and efficacy of this site- and disease-adapted SBRT fractionation approach (NCT03818503).

Interest & Impact

Downloads

0 since deposited on 28 Mar 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item